A collecting system is provided that can include a probe configured to collect pathogens from a surrounding fluid, an elution chamber containing a liquid solvent and configured to receive the probe to elute the pathogens collected on the probe using the liquid solvent, and a heater configured to lyse the pathogens to release the genetic material of the pathogens into the liquid solvent.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
B01L 7/00 - Heating or cooling apparatus; Heat insulating devices
C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
The present disclosure relates to methods and compositions for enhanced assessment of exogenous polynucleotide and/or polypeptide-mediated transcriptional perturbations at high throughput and single cell/droplet levels of resolution. In embodiments, nucleic acid fusions of exogenous polynucleotide(s) and associated target transcript(s) are produced within individually sequestered or discretely identifiable cells/lysates and analyzed for exogenous polynucleotide mediated perturbations across a vast population of droplets/cells within individual reactions. Kits for performance of the methods are also provided.
Provided herein are genetic circuits and encoded RNA transcripts that produce an output molecule in response to an RNA cleavage event that removes a degradation signal. In some embodiments, the genetic circuits described herein may be used for detecting RNA cleaver activities (e.g., in a cell). Methods of using the genetic circuits described herein in diagnostic or therapeutic applications are also provided.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C12N 15/67 - General methods for enhancing the expression
In one aspect, embodiments disclosed herein are directed to engineered CRISPRCas effector proteins that comprise at least one modification compared to an unmodified CRISPR-Cas effector protein that enhances binding of the of the CRISPR complex to the binding site and/or alters editing preference as compared to wild type. In certain example embodiments, the CRISPR-Cas effector protein is a Type II effector protein. In certain other example embodiments, the Type V effector protein is Cas9 or an orthologs or engineered variant thereof. Example Cas9 proteins suitable for use in the embodiments disclosed herein are discussed in further detail below.
This disclosure provides a method for imaging lymph nodes and lymphatic vessels without a contrast agent. The method includes providing, using an optical source, an infrared illumination to a region of a subject having at least one lymphatic component, detecting a reflected portion of the infrared illumination directly reflected from the region using a sensor positioned thereabout, and generating at least one image indicative of the at least one lymphatic component in the subject using the reflected portion of the infrared illumination.
G01N 21/35 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
Meta-lens based ocular imaging, near-eye display, and eye-tracking systems are described. The systems can include a single focusing optic and an integrated circuit that provides illumination light and includes an imaging array. The focusing optic includes meta-atoms formed on a substrate. The systems may have no moving parts and achieve imaging or image-projection fields-of-view approaching or exceeding 180 degrees. Because of their low part count, the systems can be robust and have a very small form factor.
A61B 3/14 - Arrangements specially adapted for eye photography
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
G02B 1/00 - Optical elements characterised by the material of which they are made; Optical coatings for optical elements
G02B 27/00 - Optical systems or apparatus not provided for by any of the groups ,
Described herein are systems and methods for the generation of bio-based plasticizers from lignin from 4-hydroxybenzoic acid (H), vanillic acid (G) and syringic acid (S) obtained via oxidative depolymerization of lignin substrates. Chemical and electrochemical methods are described for catalytic reductive coupling of sulfonate derivatives of H, G and S to generate all possible homo- and cross-coupling products. Advantageously, the provided systems and methods allow for the generation of renewable plasticizers that exhibit performance advantages relative to established petroleum-based phthalate ester plasticizers.
B01J 23/89 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with noble metals
C07C 303/08 - Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof by substitution of hydrogen atoms by sulfo or halosulfonyl groups by reaction with halogenosulfonic acids
C08K 5/12 - Esters; Ether-esters of cyclic polycarboxylic acids
9.
ULTRA-HIGH-VOLTAGE RECHARGEABLE BATTERIES WITH SULFONAMIDE-BASED ELECTROLYTES
An electrochemical device includes a transition metal oxide cathode, such as LiNi0.8Co0.1Mn0.1O2, and an electrolyte. The electrolyte includes N, N-dimethyltrifluoromethane-sulfonamide (DMTMSA) and lithium bis(fluorosulfonyl)imide (LiFSI). The DMTMSA and LiFSI may be either the primary component of the electrolyte or an additive in the electrolyte. The electrochemical device may also include a graphite anode or a lithium metal anode. With a lithium metal anode, the electrochemical device has an initial specific capacity of at least 231 mAh g−1. Over at least 100 cycles (upper cut-off voltage of 4.7±0.05 V vs. Li/Li+), the electrochemical device maintains an average specific capacity of at least 88% of the initial specific capacity and an average Coulombic efficiency of at least about 99.65%.
H01M 10/0569 - Liquid materials characterised by the solvents
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
Methods, systems, and computer program products for translating text using generated visual representations and artificial intelligence are provided herein. A computer-implemented method includes generating a tokenized form of at least a portion of input text in a first language; generating at least one visual representation of at least a portion of the input text using a first set of artificial intelligence techniques; generating a tokenized form of at least a portion of the at least one visual representation; and generating an output including a translated version of the input text into at least a second language by processing, using a second set of artificial intelligence techniques, at least a portion of the tokenized form of the at least a portion of the input text and at least a portion of the tokenized form of the at least a portion of the at least one visual representation.
The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.
The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.
Articles and methods for processing aluminum are generally described. The aluminum can include compositions of gallium and/or indium such that the aluminum is activated to react with water.
The present disclosure describes photonic materials that reversibly change color in response to the material being stretched or otherwise mechanically deformed.
Methods and systems for the fabrication of composite materials are generally described. Certain inventive methods and systems can be used to fabricate composite materials with few or no defects. According to certain embodiments, composite materials are fabricated without the use of an autoclave. In some embodiments, composite materials are fabricated in low pressure environments.
What is described herein is a device for sensing a target, comprising a planar array of unique stochastic sensors, wherein each sensor is weakly cross-reactive with a unique determinant on the target; a means for capturing electrical signals from each sensor and the temporal duration of each signal; and a means for analyzing the cumulative signals from the array of stochastic sensors, and optionally further comprising a computer system for processing an algorithm for identifying the target based on the electrical signals from the sensors of the device.
System, methods, and other embodiments described herein relate to training a scene simulator for rendering 2D scenes using data from real and simulated agents. In one embodiment, a method includes acquiring trajectories and three-dimensional (3D) views for multiple agents from observations of real vehicles. The method also includes generating a 3D scene having the multiple agents using the 3D views and information from simulated agents. The method also includes training a scene simulator to render scene projections using the 3D scene. The method also includes outputting a 2D scene having simulated observations for a driving scene using the scene simulator.
G09B 9/042 - Simulators for teaching or training purposes for teaching control of vehicles or other craft for teaching control of land vehicles providing simulation in a real vehicle
G09B 9/05 - Simulators for teaching or training purposes for teaching control of vehicles or other craft for teaching control of land vehicles the view from a vehicle being simulated
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16B 40/00 - ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
The present application provides systems, methods and compositions used for targeted gene modification, targeted insertion, perturbation of gene transcripts, nucleic acid editing. Novel nucleic acid targeting systems comprise components of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems and transposable elements. Specifically, the disclosure provides an engineered composition comprising: a programmable DNA-binding protein and two or more Tn7-like transposition proteins, wherein at least one of the Tn7-like transposition proteins is connected to the DNA-binding protein or otherwise capable of forming a complex with the DNA-binding protein, wherein the DNA-binding protein comprising a Cas protein including a Cas12k protein, and wherein two or more Tn7-like transposition proteins consisting of TnsB, TnsC, and TniQ.
C12N 15/90 - Stable introduction of foreign DNA into chromosome
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
An orbital tensile drive is herein disclosed, along with systems and methods associated therewith. The orbital tensile drive uses a tensile element that is conveyed around a static, fixed shaft and a rotating output shaft. This is facilitated via multiple orbiting idler pulleys that are mounted to an orbiter body. The static and rotating shafts, as well as the orbiting assembly, share a common axis. Input rotation to the orbiter body is transformed into lower-speed, higher-torque rotation at the rotating output shaft. The present invention has many potential applications including, but not limited to, robotics.
The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.
Drug delivery articles, resident articles, and retrieval systems e.g., for gram-level dosing, are generally provided. In some embodiments, the residence articles are configured for transesophageal administration, transesophageal retrieval, and/or gastric retention to/in a subject. In certain embodiments, the residence article includes dimensions configured for transesophageal administration with a gastric resident system. In some cases, the residence article may be configured to control drug release e.g., with zero-order drug kinetics with no potential for burst release for weeks to months. In some embodiments, the residence articles described herein comprise biocompatible materials and/or are safe for gastric retention. In certain embodiments, the residence article includes dimensions configured for transesophageal retrieval. In some cases, the residence articles described herein may comprise relatively large doses of drug (e.g., greater than or equal to 1 gram).
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
23.
FUNCTIONAL GENOMICS USING CRISPR-CAS SYSTEMS FOR SATURATING MUTAGENESIS OF NON-CODING ELEMENTS, COMPOSITIONS, METHODS, LIBRARIES AND APPLICATIONS THEREOF
The application relates to a deep scanning mutagenesis library to interrogate phenotypic changes in a population of cells comprising a plurality of CRISPR-Cas system guide RNAs targeting genomic sequences within at least one continuous genomic region, wherein the guide RNAs target at least 100 genomic sequences upstream of a PAM sequence for every 1000 base pairs within the continuous genomic region and methods for their use.
This disclosure provides systems, methods, and compositions for site specific genetic engineering comprising the use of CRISPR effectors and trans-splicing. The disclosure also relates to methods of using the systems and compositions for treating diseases as well as diagnostics.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 43/00 - Drugs for specific purposes, not provided for in groups
A method is directed to continuously, non-invasively, and directly measuring blood pressure, and includes providing a calibrated measurement device having a blood-flow control balloon and a sensor array. The method further includes placing the sensor array in a non-invasive manner over the surface of a patch of skin connected to an artery by adjoining soft tissues and inflating the blood-flow control balloon with a controlled amount of pressure. In response to the inflating of the blood-flow control balloon, changes in the artery geometry and forces are detected, via the sensor array, during a heartbeat cycle. The changes correspond to spatio-temporal signals from the artery or in the adjoining soft tissues. The spatio-temporal signals are measured and processed, via a controller, to determine blood-pressure parameters.
A61B 5/022 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skin; Ophthaldynamometers
A61B 5/02 - Measuring pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography; Heart catheters for measuring blood pressure
A61B 5/107 - Measuring physical dimensions, e.g. size of the entire body or parts thereof
A61B 8/08 - Detecting organic movements or changes, e.g. tumours, cysts, swellings
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventor
Hwang, Theresa
Keating, Amy E.
Ilunga, Meucci
Parker, Sara
Mouneimne, Ghassan
Hill, Samantha
Abstract
Peptides that selectively bind ENAH (MENA) are described. The peptides are useful for treating certain cancers, such as triple negative breast cancer and for reducing resistance to taxane therapy.
Glycan-binding proteins, and compositions thereof, are generally described, including methods of making and using such proteins. The proteins may include scaffolds based on easily evolvable DNA-binding proteins, with binding sites able to specifically bind to mono- or disaccharides, such as monosaccharide-binding determinants, disaccharide-binding determinants, more complex carbohydrates, etc. In certain aspects, a protein may be generated starting from a small DNA-binding protein, such as Sso7d. Such glycan-binding proteins may have numerous applications, including in enzyme-linked immunosorbent assays (ELISAs), glycan characterization, cell selection, flow cytometry, histology, imaging, arrays, affinity purification, enzyme-linked visualization, binding to a target for pharmaceutical purposes, etc.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
28.
Integrating Biopolymer Design with Physical Unclonable Functions for Anticounterfeiting and Product Traceability
Compositions are provided that include a first product with a physical unclonable function (PUF) tag including silk particles conformably and directly attached to the first product, wherein the PUF tag cannot be reattached to a second product once removed from the first product.
H04L 9/32 - Arrangements for secret or secure communications; Network security protocols including means for verifying the identity or authority of a user of the system
29.
POLYETHYLENE TEXTILES WITH ENGINEERED FEATURES THAT PROVIDE FOR PASSIVE COOLING AND MANUFACTURE THEREOF
INSTITUTO TECHNOLOGICO Y DE ESTUDIOS SUPERIORES DE MONTERREY (Mexico)
Inventor
Boriskina, Svetlana V.
Chen, Gang
Lozano Sanchez, Luis Marcelo
Alberghini, Matteo
Abstract
The present disclosure generally relates to textiles that are optimized to maximize moisture wicking and evaporative performance thereof. In some embodiments, raw polyethylene (PE) powder can be extruded into fibers that can be modified by oxidation along a surface thereof to increase hydrophilicity of the surface. Once sufficiently oxidized, the fibers can be bundled to form multi-filament yarns that can then be spun, weaved, knitted, and/or otherwise associated with one another to form a polyethylene fabric. The PE fibers can be further modified to increase a capillary force of the bundle, thereby further increasing hydrophilicity of the resulting fabric. Engineering of the capillary force can be performed by optimizing one or more of a fiber size, a density, or a cross-section of the fibers and/or the bundles. The resultant fabric can exhibit a strong weight reduction, stain resistance, and drying capabilities, among other capabilities.
D06M 10/00 - Physical treatment of fibres, threads, yarns, fabrics or fibrous goods made from such materials, e.g. ultrasonic, corona discharge, irradiation, electric currents or magnetic fields; Physical treatment combined with treatment with chemical compounds or elements
D06M 10/02 - Physical treatment of fibres, threads, yarns, fabrics or fibrous goods made from such materials, e.g. ultrasonic, corona discharge, irradiation, electric currents or magnetic fields; Physical treatment combined with treatment with chemical compounds or elements ultrasonic or sonic; Corona discharge
The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are stmctural information on the Cas protein of the CRISPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formulation in eukaryotic cells and methods for utilizing the CRISPR-Cas system. In particular the present invention comprehends optimized functional CRISPR-Cas enzyme systems.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A computer implemented method for certifying robustness of image classification in a neural network is provided. The method includes initializing a neural network model. The neural network model includes a problem space and a decision boundary. A processor receives a data set of images, image labels, and a perturbation schedule. Images are drawn from the data set in the problem space. A distance from the decision boundary is determined for the images in the problem space. A re-weighting value is applied to the images. A modified perturbation magnitude is applied to the images. A total loss function for the images in the problem space is determined using the re-weighting value. A confidence level of the classification of the images in the data set is evaluated for certifiable robustness.
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/774 - Generating sets of training patterns; Bootstrap methods, e.g. bagging or boosting
Provided herein are peptides that bind Mcl-1. Also provided are compositions containing these polypeptides and methods of using such peptides in the treatment of cancer that include administering to a subject one of the polypeptides.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
A method for the systemic delivery of a polypeptide within a subject is provided by creating genetically modified skin cells via topical introduction of a genetically engineered virus which delivers a nucleic acid encoding a therapeutic polypeptide for expression by the skin cells, wherein the expressed therapeutic polypeptide is secreted by the skin cells and is introduced into the circulatory system of the subject.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Deutsches Rheuma-Forschungszentrum Berlin, ein Leibniz-Institut (Germany)
Charité - Universitätsmedizin Berlin (Germany)
Inventor
Birnbaum, Michael
Huisman, Brooke
Romagnani, Chiara
Rückert, Timo
Abstract
Peptides capable of binding to HLA-E and affecting immune cell activity are provided. Such peptides can selectively activate NKG2C+ immune cells such as natural killer (NK) cells and/or can inhibit NKG2A+ cells to decrease or suppress immune cell responses. Methods of use of the peptides are also disclosed, for instance, for treating or inhibiting the development or progression of a multitude of illnesses and conditions, including autoimmune disease, infectious disease such as viral or bacterial infection, and proliferative disorders such as cancer.
According to one aspect of the disclosure, a mobile augmented reality (AR) system can include: a receiver configured to receive radio frequency (RF) signals from one or more items located within an environment; a tracking module configured to generate tracking data responsive to a location of the system within the environment over time; a display device; and one or more processors configured to determine a location of at least one of the one or more items within the environment using the received RF signals and the tracking data, and generate a visual representation of the location of the at least one item for display on the display device.
A wind turbine generator includes a stator having a plurality of high-temperature superconducting coils. A current is driven through the high-temperature superconducting coils to produce a magnetic field. A rotor comprising one or more phase coils is physically coupled to a wind turbine. As the wind turbine turns the rotor, current is induced in the one or more phase coils to produce electrical power. The phase coils may include conductive material, superconducting material, and/or high-temperature superconducting material.
Provided herein are compositions, systems, and methods for delivering cargo to a target cell. The compositions, systems, and methods comprise one or more polynucleotides encoding one or more LTR retroelement polypeptides for forming a delivery vesicle and one or more capture moieties for packaging a cargo within the delivery vesicle. The one or more LTR retroelement polypeptides for forming a delivery vesicle may comprise two or more of an LTR retroelement gag protein, a retroelement envelope protein, a an LTR retroelement reverse transcriptase, or a combination thereof. The LTR retroelement polypeptide alone, the LTR retroelement envelope protein alone, or both the LTR retroelement-derived polypeptide and LTR retroelement envelope protein may be endogenous.
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
The present disclosure relates to compositions and methods for treating Williams syndrome (WS), herein identified as a neurodevelopmental oligodendrocyte hypomyelination-associated disease, and to compositions and methods for treatment of other neurodevelopmental myelination abnormality diseases or disorders.
A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4409 - Non-condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
39.
COMPOSITIONS FOR CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY AND USES THEREOF
The disclosure features amphiphilic ligand conjugates comprising a chimeric antigen receptor (CAR)ligand and a lipid. The disclosure also features compositions and methods of using the same, for example, to stimulate proliferation of CAR expressing cells.
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
40.
CONSTRUCTS FOR CONTINUOUS MONITORING OF LIVE CELLS
The present invention provides for methods to obtain multiple information-rich samples at different time points from the same cell while minimally disrupting the cell. The subject matter disclosed herein is generally related to nucleic acid constructs for continuous monitoring of live cells. Specifically, the subject matter disclosed herein is directed to nucleic acid constructs that encode a fusion protein and a construct RNA sequence that induce live cells to self-report cellular contents while maintaining cell viability. The present invention may be used to monitor gene expression in single cells while maintaining cell viability.
C12N 15/62 - DNA sequences coding for fusion proteins
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
41.
Protection of Next-Generation Probiotics during Processing
Prokaryotic cells having a metal-phenolic network coating are disclosed, as are compositions including such cells, methods for their use, and methods for producing such cells.
A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/52 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
42.
Software and Methods for Controlling Neural Responses in Deep Brain Regions
Techniques for non-invasively controlling targeted neural activity of a subject are provided herein. The techniques include applying a stimulus input to the subject, the stimulus input being formed by a deep artificial neural network (ANN) model and being configured to elicit targeted neural activity within a brain of the subject. The stimulus input may be a pattern of luminous power generated by the deep ANN model and applied to retinae of the subject. The stimulus input may be generated by the deep ANN model based on a mapping of the subject's neural responses to neurons of the deep ANN model.
A61M 21/00 - Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
The present disclosure is related to porous media with adjustable fluid permeabilities and related systems and methods. In certain cases, the fluid permeability of a porous medium can be adjusted by applying an electrical potential to the porous medium. In some such cases, the application of the electrical potential to the porous medium results in the deposition of material over or the removal of material from the porous medium. Also disclosed herein are systems and methods for capturing species (e.g., acid gases) in which porous media with adjustable fluid permeabilities are used, for example, to control the flow of fluid into and out of a medium used to capture the species.
B01D 53/32 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by electrical effects other than those provided for in group
B01D 53/22 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
Polymeric electro spray emitters and related methods are generally described. In some embodiments, an emitter may be made from an ionic electro active polymer. The composition of the electro spray emitters described herein may enable the transport of ions and/or liquid ion sources, such as an ionic liquid or room temperature molten salt, through the bulk of the polymeric emitter. In some embodiments, the described emitters may be fabricated using a mixture of an ionic electroactive polymer, a solvent, and a liquid ion source to at least partially mitigate swelling effects of the polymer emitter that may otherwise occur when the one or more emitters are exposed to the liquid ion source during operation.
This disclosure provides a method for substantially increasing the concentration of cfDNA in a patient. By injecting a patient with lipid and/or polymer nanoparticles, agents that bind cfDNA, or inhibit deoxyribonucleases prior to collection of a sample of cfDNA, e.g., by way of a liquid biopsy, major pathways for the degradation of cfDNA are temporarily blocked, permitting transient accumulation of cfDNA. This strategy has the potential to dramatically enhance the quality of detection achieved by downstream cfDNA e analytical applications, such as sequencing applications.
The present invention relates to the analysis of complex single cell sequencing libraries. Disclosed are methods for enrichment of library members based on the presence of cell-of origin barcodes to identify and concentrate DNA that is relevant to interesting cells or components that would be expensive or difficult to study otherwise. Also, disclosed are methods of capturing cDNA library molecules by use of CRISPR systems, hybridization or PCR. The present invention allows for identifying the properties of rare cells in single cell RNA-seq data and accurately profile them through clustering approaches. Further information on transcript abundances from subpopulations of single cells can be analyzed at a lower sequencing effort. The methods also allow for linking TCR alpha and beta chains at the single cell level.
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
C40B 40/06 - Libraries containing nucleotides or polynucleotides, or derivatives thereof
C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof
C40B 50/06 - Biochemical methods, e.g. using enzymes or whole viable microorganisms
The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed.
A reticle transport system having a magnetically levitated transportation stage is disclosed. Such a system may be suitable for use in vacuum environments, for example, ultra-clean vacuum environments. A magnetic levitated linear motor functions to propel the transportation stage in a linear direction along a defined axis of travel and to magnetically levitate the transportation stage
G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfaces; Materials therefor, e.g. comprising photoresists; Apparatus specially adapted therefor
This disclosure provides systems, methods, and compositions for site-specific genetic engineering using Programmable Addition via Site-Specific Targeting Elements (PASTE). PASTE comprises the addition of an integration site into a target genome followed by the insertion of one or more genes of interest or one or more nucleic acid sequences of interest at the site. PASTE combines gene editing technologies and integrase technologies to achieve unidirectional incorporation of genes in a genome for the treatment of diseases and diagnosis of disease.
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Quantum information processing involves entangling large numbers of qubits, which can be realized as defect centers in a solid-state host. The qubits can be implemented as individual unit cells, each with its own control electronics, that are arrayed in a cryostat. Free-space control and pump beams address the qubit unit cells through a cryostat window. The qubit unit cells emit light in response to these control and pump beams and microwave pulses applied by the control electronics. The emitted light propagates through free space to a mode mixer, which interferes the optical modes from adjacent qubit unit cells for heralded Bell measurements. The qubit unit cells are small (e.g., 10 μm square), so they can be tiled in arrays of up to millions, addressed by free-space optics with micron-scale spot sizes. The processing overhead for this architecture remains relatively constant, even with large numbers of qubits, enabling scalable large-scale quantum information processing.
An active acoustic system includes a thin-film sheet having an array of piezoelectric microstructures embossed in the film. Each piezoelectric microstructure may act as a speaker and/or a microphone. A control circuit is configured to individually address the piezoelectric microstructures to provide a separate voltage signal to, or receive a separate voltage signal from, each piezoelectric microstructure.
H04R 1/40 - Arrangements for obtaining desired frequency or directional characteristics for obtaining desired directional characteristic only by combining a number of identical transducers
The invention provides for systems, methods, and compositions for targeting and editing nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a DNA-targeting Cpf1 protein, at least one guide molecule, and at least one adenosine deaminase protein or catalytic domain thereof.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Bi-modal propulsion systems and related methods are generally described. In some embodiments, a bi-modal propulsion system may employ a single propellant for both chemical thruster(s), operating at elevated pressures, and electrical thruster(s) (e.g., electro spray thruster), operating at reduced pressures. The propellant pressure may be reduced to a desired operational range of the electrical thruster(s) using any appropriate construction including, for example, capillaries configured to reduce the pressure of the propellant to an operational range of the electrical thruster(s). In some embodiments, the reduced pressure of the propellant may be lower than a vapor pressure of at least one volatile component of the propellant, leading to the formation of “bubbles” within the propellant line. The presence of alternating gas and liquid phases along a flow path between a propellant tank and the electrical thruster(s) may help to electrically insulate the electrical thruster from the rest of the system.
A method includes receiving data representing graphomotor motion during a succession of executions of graphomotor diagnostic tasks performed in a medical context by a subject, processing the received data using a computer, including determining a first set of quantitative features from a first execution of a task by the subject, and determining a second set of quantitative features from a second execution of a task by the subject, determining one or more metrics based on a comparison to the successive executions, including using at least the first set of quantitative features and the second set of quantitative features to determine said metrics, and providing a diagnostic report associated with neurocognitive mechanisms underlying the subject's execution of the tasks based on the determined metrics.
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/16 - Devices for psychotechnics; Testing reaction times
G06Q 10/101 - Collaborative creation, e.g. joint development of products or services
G06Q 50/00 - Systems or methods specially adapted for specific business sectors, e.g. utilities or tourism
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
55.
AUTOMATED METHODS FOR SCALABLE, PARALLELIZED ENZYMATIC BIOPOLYMER SYNTHESIS AND MODIFICATION USING MICROFLUIDIC DEVICES
Methods for the automated template-free synthesis of user-defined sequence controlled biopolymers using microfluidic devices are described. The methods facilitate simultaneous synthesis of up to thousands of uniquely addressed biopolymers from the controlled movement and combination of regents as fluid droplets using microfluidic and EWOD-based systems. In some forms, biopolymers including nucleic acids, peptides, carbohydrates, and lipids are synthesized from step-wise assembly of building blocks based on a user-defined sequence of droplet movements. In some forms, the methods synthesize uniquely addressed nucleic acids of up to 1,000 nucleotides in length. Methods for adding, removing and changing barcodes on biopolymers are also provided. Biopolymers synthesized according to the methods, and libraries and databases thereof are also described. Modified biopolymers, including chemically modified nucleotides and biopolymers conjugated to other molecules are described.
Two-dimensional (2D) materials and their heterostructures show a promising path for next generation electronics. Nevertheless, there are challenges with (i) controlling monolayer (ML)-by-ML 2D material growth, (ii) maintaining single-domain growth, and (iii) controlling the number of layers and crystallinity at the wafer-scale. The deterministic confined growth techniques disclosed here address these challenges simultaneously to produce wafer-scale single-domain 2D MLs and their heterostructures on arbitrary substrates. The growth of the first nuclei is confined by patterning SiO2 masks on 2-inch substrates to define selective or confined growth areas. Each growth area or trench is just a few microns wide and is filled with a single-domain ML before the second set of nuclei is introduced. Growing the second set of nuclei within the trenches yields an array of single-domain bilayers at the 2-inch wafer scale. Devices made with the single-domain bilayers exhibit excellent performance over the entire wafer.
Schemes are described for joint geometry and placement in superconducting magnets. According to some aspects, a joint may be implemented in a modular component of a superconducting magnet, such as a plate that includes a spiral superconducting path, with the joints providing electrically conductive connections between the superconducting paths of adjacent plates. A joint may be installed and coupled to the component (e.g., plate) after its fabrication, thereby providing freedom in design of both the joint and the component. In at least some cases, the joints may be arranged to be flush with a surface of the component after installation into the component so that neighboring instances of the components may be stacked flush with one another, thereby putting joints from the neighboring components into intimate contact with one another.
Genetic circuits that control transgene expression in response to pre-defined transcriptional cues would enable the development of smart therapeutics. The present disclosure relates to engineered programmable single-transcript RNA sensors in which adenosine deaminases acting on RNA (ADARs) autocatalytically convert trigger hybridization into a translational output. This system amplifies the signal from editing by endogenous ADAR through a positive feedback loop. Amplification is mediated by the expression of a hyperactive, minimal ADAR variant and its recruitment to the edit site via an orthogonal RNA targeting mechanism. This topology confers high dynamic range, low background, minimal off-target effects, and a small genetic footprint. The circuits and systems disclosed herein leverage an ability to detect single nucleotide polymorphisms and modulate translation in response to endogenous transcript levels in mammalian cells.
Embodiments disclosed herein provide a pan-tissue cell atlas of healthy and diseased subjects obtained by single cell sequencing. The present invention discloses novel markers for cell types. Moreover, genes associated with disease, including HIV infection and tuberculosis are identified. The invention provides for diagnostic assays based on gene markers and cell composition, as well as therapeutic targets for controlling immune regulations and cell-cell communication of the cell types disclosed herein. In addition, novel cell types and methods of quantitating, detecting and isolating the cell types are disclosed.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
60.
Systems, methods, and compositions for site-specific genetic engineering using programmable addition via site-specific targeting elements (paste)
This disclosure provides systems, methods, and compositions for site-specific genetic engineering using Programmable Addition via Site-Specific Targeting Elements (PASTE). PASTE comprises the addition of an integration site into a target genome followed by the insertion of one or more genes of interest or one or more nucleic acid sequences of interest at the site. PASTE combines gene editing technologies and integrase technologies to achieve unidirectional incorporation of genes in a genome for the treatment of diseases and diagnosis of disease.
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
The present invention describes photoluminescent apparatuses or colour filters (100a,100b,100c,100d) and methods (1000a,1000b) for manufacturing. A photoluminescent (PL) or quantum dot (QD) material (100) fills a pattern of trenches (40,42) formed on a surface or on opposite surfaces of an optically transparent substrate (20), being cured and sealed by an optically transparent cover (22); in another embodiment, the PL or QD material (100) are cured and sealed when two patterned optically substrates (20) are bonded together. Sealing of the PL or QD material in the trenches (40,42) preserves the optical and performance stability of these colour filters. These colour filters (100a, . . . 100d) are suitable for use in next generation UHD display screens or lighting applications.
B01D 29/86 - Retarding cake deposition on the filter during the filtration period, e.g. using stirrers
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
B01D 29/05 - Filters with filtering elements stationary during filtration, e.g. pressure or suction filters, not covered by groups ; Filtering elements therefor with flat filtering elements supported
B01D 29/60 - Filters with filtering elements stationary during filtration, e.g. pressure or suction filters, not covered by groups ; Filtering elements therefor integrally combined with devices for controlling the filtration
Methods and systems are described for precisely adjusting characteristics of microfabricated devices after device fabrication. The adjustments can be carried out in parallel on a plurality of the microfabricated devices. By carrying out the adjustment process, uniformity of feature sizes to a few picometers (one standard deviation) and corresponding uniformity of operating characteristics for a plurality of microfabricated devices are possible.
G02F 1/025 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour based on semiconductor elements with at least one potential jump barrier, e.g. PN, PIN junction in an optical waveguide structure
Disclosed herein is a wearable article, comprising a fabric. In some embodiments, the fabric comprises an inner material layer which forms an inner surface of the wearable article, an outer material layer which forms an outer surface of the wearable article; and one or more intermediate material layers disposed between the inner and outer material layers. In some embodiments, the inner, outer, and one or more intermediate material layers are knitted together to provide a combination of two or more of: two or more compression zones; two or more mobility zones; two or more materials; or one or more electronic components.
B32B 5/06 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by structural features of a layer comprising fibres or filaments characterised by a fibrous layer needled to another layer, e.g. of fibres, of paper
B32B 7/05 - Interconnection of layers the layers not being connected over the whole surface, e.g. discontinuous connection or patterned connection
B32B 7/02 - Physical, chemical or physicochemical properties
B32B 5/02 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by structural features of a layer comprising fibres or filaments
B32B 5/26 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by the presence of two or more layers which comprise fibres, filaments, granules, or powder, or are foamed or specifically porous one layer being a fibrous or filamentary layer another layer also being fibrous or filamentary
A41D 13/12 - Surgeons' or patients' gowns or dresses
Faults in rotating machines can be diagnosed or detected using two radio frequency (RF) sensing modes. RF sensing phenomenon can be used to detect the presence of undesirable behavior in rotating machines including excessive bending, vibration, eccentricity, torsion, and longitudinal strain. RF based sensors represent a non-invasive solution. The sensing modes are based on RF metamaterials and Doppler effect influence and radar cross section evaluation all coupled with a machine learning algorithm. The system is based on monitoring resonance shift, negative permeability and return loss magnitudes. Electromagnetic numerical simulations showed a significant change in those magnitudes upon applied mechanical strains as compared to original reference unstrained cases. Metamaterial texturing design can be controlled by controlling the cells scale and substrate materials.
G01S 13/88 - Radar or analogous systems, specially adapted for specific applications
G01H 9/00 - Measuring mechanical vibrations or ultrasonic, sonic or infrasonic waves by using radiation-sensitive means, e.g. optical means
G01S 7/41 - RADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES - Details of systems according to groups , , of systems according to group using analysis of echo signal for target characterisation; Target signature; Target cross-section
66.
RETROGRAPHIC SENSORS WITH FLUORESCENT ILLUMINATION
A retrographic sensor includes a transparent structure, a transparent elastomeric pad, and an at least partially reflective layer. One or more excitation light sources emit light toward a side surface of the transparent structure. The side surface may include a fluorescent layer, where the light from the one or more excitation light sources excites fluorescent emissions from the fluorescent layer. The fluorescent emissions may illuminate the at least partially reflective layer.
G01L 1/24 - Measuring force or stress, in general by measuring variations of optical properties of material when it is stressed, e.g. by photoelastic stress analysis
G01L 5/166 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes for measuring several components of force using photoelectric means
G01L 5/22 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes for measuring the force applied to control members, e.g. control members of vehicles, triggers
67.
APPARATUS AND METHOD FOR CONTROL OF HEAVY OBJECT TUMBLING
Autonomous systems for control of heavy object tumbling and related methods are generally described. In some embodiments, the autonomous system may include one or more tethers connected to a heavy object, each tether position and location controlled by one or more actuators. The control system may include one or more processors in communication with the actuators to maintain constant quasi-static control of the heavy object during a tumbling process, in which the object is manipulated (e.g., rotated about an axis relative to a supporting surface) to provide access to alternate faces of the object. In some embodiments, the control system may reduce the risk of uncontrollable tumbling by alternating between position and tension control of the tethers depending on the orientation of the object and/or progression of the tumbling process.
A visibly transparent luminescent solar concentrator (LSC) is disclosed. The LSC includes a transparent substrate having at least one edge surface. A dye layer is coupled to the substrate, the dye layer having a peak absorption wavelength outside the visible band, the dye layer being configured to re-emit light at a peak emission wavelength outside the visible band, at least a portion of the re-emitted light being waveguided to the edge surface of the substrate. A photovoltaic device is coupled to the edge surface of the transparent substrate, the photovoltaic device being configured to absorb light at the peak emission wavelength and generate electrical energy.
H01L 31/055 - Optical elements directly associated or integrated with the PV cell, e.g. light-reflecting means or light-concentrating means where light is absorbed and re-emitted at a different wavelength by the optical element directly associated or integrated with the PV cell, e.g. by using luminescent material, fluorescent concentrators or up-conversion arrangements
69.
Fiber Comprising Micro Devices and Metal Interconnects with Controlled Elasticity
An elastic and conductive fiber includes a cladding with a channel and a conductor disposed therein. The cladding may be made of a thermoplastic elastomer. The conductive fiber includes an excess length of conductor disposed inside of the channel so that the conductive fiber can stretch without applying substantial strain to the conductor and without substantially changing the electrical resistance of the conductive fiber. The conductor inside of the channel may have a buckled shape or a helical shape.
H01B 7/04 - Flexible cables, conductors, or cords, e.g. trailing cables
H01B 1/02 - Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors mainly consisting of metals or alloys
H01B 3/44 - Insulators or insulating bodies characterised by the insulating materials; Selection of materials for their insulating or dielectric properties mainly consisting of organic substances waxes acrylic resins
D03D 15/292 - Conjugate, i.e. bi- or multicomponent, fibres or filaments
D03D 1/00 - Woven fabrics designed to make specified articles
D04B 1/16 - Other fabrics or articles characterised primarily by the use of particular thread materials synthetic threads
D03D 15/283 - Woven fabrics characterised by the material, structure or properties of the fibres, filaments, yarns, threads or other warp or weft elements used characterised by the material of the fibres or filaments constituting the yarns or threads synthetic polymer-based, e.g. polyamide or polyester fibres
D03D 15/30 - Woven fabrics characterised by the material, structure or properties of the fibres, filaments, yarns, threads or other warp or weft elements used characterised by the structure of the fibres or filaments
70.
Sulfide Reactive Vacuum Distillation, Absorption, Stripping, and Extraction for Metal and Alloy Production
In accordance with one embodiment, a method comprises dissolving a sulfide of a first metal in a solvent comprising molten aluminum; aluminothermically reduce at least a portion of the sulfide through reactive vacuum distillation to form gaseous aluminum sulfide distillate and elemental first metal that remains in the molten aluminum; and at least one of (e.g., one, two, or all three of) (a) reacting the aluminum sulfide distillate with at least one material in the molten aluminum; (b) reacting the aluminum sulfide distillate with at least one material outside of the molten aluminum; or (c) condensing the gaseous aluminum sulfide distillate.
A flow control system that produces smooth flow for on-chip pneumatic micropumps has been developed. By establishing a flow control system that can achieve smooth flow, fluidic conditions of microphysiological systems can be controlled to accurately mimic biological conditions. Biological experiments can require flow profiles anywhere on the spectrum of smooth flow to highly pulsatile flow. A smooth flow profile can be modified with pumping delays to make the flow profile as pulsatile as desired.
Described herein, is a sensing textile for a spacecraft, comprising an aerospace-grade fabric substrate having a surface and one or more sensing fibers coupled to the aerospace-grade fabric substrate, wherein at least a subset of the sensing fibers extends above the surface of the substrate. In some embodiments, the sensing fibers comprises one or more of an impact sensor, a charge sensor, a thermal sensor or radiative surface. Some embodiments, the sensing fibers are configured to form one or more patterned topologies about the surface of the aerospace-grade fabric substrate. In some embodiments, the patterned topologies comprises one or more of a pile, looped pile, waffle, spacer, seersucker, plissé, or an embroidery.
B64G 1/68 - Arrangements or adaptations of apparatus or instruments, not otherwise provided for of meteoroid or space debris detectors
H10N 30/00 - Piezoelectric or electrostrictive devices
H10N 30/30 - Piezoelectric or electrostrictive devices with mechanical input and electrical output, e.g. functioning as generators or sensors
D06M 11/83 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with metal-generating compounds, e.g. metal carbonyls; Reduction of metal compounds on textiles
73.
PANCREATIC DUCTAL ADENOCARCINOMA SIGNATURES AND USES THEREOF
Described herein are pancreatic ductal adenocarcinoma (PDAC) signatures and methods of detecting the same in a sample from heterogeneity-score a subject. Also described herein, are methods of methods of diagnosing, prognosing, and/or treating PDAC in a subject that can include detecting one or more of the PDAC signatures.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
74.
Method for Synthesizing High-Rate Capability Cement-Carbon Supercapacitor
A structural supercapacitor, and methods of manufacturing, composed of a conductive composite is described herein. An embodiment of the composite has a controllable transport porosity, that enables transport of electrical charge, via electrolyte solution, to a distributed conductive network within the composite. The distributed conductive network has a controllable storage porosity that enables the storage of electrical charge. The conductive composite can be used in a variety of different fields of use, including, for example, a structural super-capacitor as an energy solution for autonomous housing and other buildings, a heated cement for pavement de-icing or house basement insulation against capillary rise, a protection of concrete against freeze-thaw (FT) or alkali silica reaction (ASR) or other crystallization degradation processes, and as a conductive cable, wire, or concrete trace.
H01G 11/08 - Structural combinations, e.g. assembly or connection, of hybrid or EDL capacitors with other electric components, at least one hybrid or EDL capacitor being the main component
H02J 7/34 - Parallel operation in networks using both storage and other dc sources, e.g. providing buffering
H01G 11/38 - Carbon pastes or blends; Binders or additives therein
C04B 38/08 - Porous mortars, concrete, artificial stone or ceramic ware; Preparation thereof by adding porous substances
H02J 7/00 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
King Fahd University of Petroleum & Minerals (Saudi Arabia)
Inventor
Govindan, Prakash Narayan
Thiel, Gregory P.
Mcgovern, Ronan K.
Lienhard, John H.
Elsharqawy, Mostafa H.
Abstract
A method for condensing a vapor uses a multi-stage bubble-column vapor mixture condenser that includes at least a first stage, a second stage, and a third stage, each with a carrier-gas inlet and outlet as well as a condensing bath and a volume of carrier gas above the condensing bath. The carrier-gas inlet of the second and third stages is in the form of a sieve plate. The first-stage condensing bath is at a temperature of 60° C. to 90° C. Carrier gas flows at a temperature above 60° C. and up to 93° C. into and through the carrier-gas inlet of the first stage, then into and through the condensing bath in the first stage, and then into and through the volume of carrier gas above the condensing bath in the first stage. The carrier gas then similarly flows through the second- and third-stage condensing baths, each of which is at least 5° C. cooler than the temperature of the condensing bath in the preceding stage. Additional carrier gas is injected through an intermediate-exchange inlet into the volume of carrier gas above the condensing bath in at least one of the first and second stages to control the heat and mass profile of the carrier gas flowing through the stages of the multi-stage bubble-column vapor mixture condenser and to thereby maintain the temperature differentials between the condensing baths in the first, second, and third stages.
B01D 5/00 - Condensation of vapours; Recovering volatile solvents by condensation
B01F 23/231 - Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids by bubbling
B01F 23/232 - Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids using flow-mixing means for introducing the gases, e.g. baffles
B01D 3/18 - Fractionating columns in which vapour bubbles through liquid with horizontal bubble plates
F24F 3/14 - Air-conditioning systems in which conditioned primary air is supplied from one or more central stations to distributing units in the rooms or spaces where it may receive secondary treatment; Apparatus specially designed for such systems characterised by the treatment of the air otherwise than by heating and cooling by dehumidification
B01D 3/00 - Distillation or related exchange processes in which liquids are contacted with gaseous media, e.g. stripping
B01D 3/20 - Bubble caps; Risers for vapour; Discharge pipes for liquid
C02F 1/04 - Treatment of water, waste water, or sewage by heating by distillation or evaporation
76.
METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS
Embodiments disclosed herein provide methods for identifying new CRISPR loci and effectors, as well as different CRISPR loci combinations found in various organisms. Class-II CRISPR systems contain single-gene effectors that have been engineered for transformative biological discovery and biomedical applications. Discovery of additional single-gene or multicomponent CRISPR effectors may enhance existing CRISPR applications, such as precision genome engineering. Comprehensive characterization of CRISPR-loci may identify novel functional roles of CRISPR loci enabling new tools for biomedicine and biological discovery. CRISPR loci have enormous feature complexity, but classification of CRISPR loci has been focused on a small fraction of highly abundant features. Increased genome sequencing has enhanced the sampling of this feature complexity.
G16B 40/00 - ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G06F 18/2413 - Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches based on distances to training or reference patterns
77.
MODIFIED BACTERIUM FOR OXALATE DEGRADATION AND USES THEREOF
C12N 1/38 - Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
78.
CROSSLINKING COMPOUNDS AND CROSSLINKED ACRYLIC POLYMERIC MATERIALS
Disclosed herein are cyclobutane-based crosslinking compounds that, when incorporated into acrylate-based polymeric materials, can produce toughened acrylate polymer networks. Also disclosed herein are polymers comprising the crosslinkers, methods of preparing toughened polymer networks using the crosslinkers, and methods of using the polymer networks.
C07C 69/757 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
C08F 36/20 - Homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, at least one having two or more carbon-to-carbon double bonds the radical having only two carbon-to-carbon double bonds unconjugated
C07C 69/753 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
79.
LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY
Disclosed herein are compositions of retroviruses and methods of using the same for gene delivery, wherein the retroviruses comprise a viral envelope protein comprising at least one mutation that diminishes its native function, a non-viral membrane-bound protein comprising a membrane-bound domain and an extracellular targeting domain.
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
C07K 14/74 - Major histocompatibility complex (MHC)
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Board of Regents, The University of Texas System (USA)
Massachusetts Institute of Technology (USA)
Inventor
Czako, Barbara
Ralvenius, William
Tsai, Li-Huei
Abstract
Disclosed herein are compounds which inhibit PU.1, pharmaceutical formulations, and methods of treatment of PU.1-mediated diseases, such as Alzheimer's disease, inflammation, and diseases related to excessive myelin uptake.
C07D 213/42 - Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 217/02 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 213/73 - Unsubstituted amino or imino radicals
C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The United States of America, as Represented by the Secretary Dept of Health and Human Services (USA)
Inventor
Yamano, Takashi
Nishimasu, Hiroshi
Zetsche, Bernd
Slaymaker, Ian
Li, Yinqing
Fedorova, Iana
Makarova, Kira
Gao, Linyi
Koonin, Eugene
Zhang, Feng
Nureki, Osamu
Abstract
The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA or RNA-targeting systems comprising a novel DNA or RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
G16C 20/30 - Prediction of properties of chemical compounds, compositions or mixtures
G16C 60/00 - Computational materials science, i.e. ICT specially adapted for investigating the physical or chemical properties of materials or phenomena associated with their design, synthesis, processing, characterisation or utilisation
The removal of acid gases (e.g., non-carbon dioxide acid gases) using sorbents that include salts in molten form, and related systems and methods, are generally described.
Genome editing tools for use in systems designed to deliver large genetic elements are disclosed herein. A genome editing system is described, which includes i) an R2 element enzyme or other non-LTR site specific retrotransposon element and ii) a payload RNA, wherein the payload RNA comprises an insertion region and optionally one or more of a 5′ homology region, a 3′ homology region, and a protein binding element, wherein the insertion region comprises a template for a small or large nucleic acid insertion into the genome, and wherein the R2 element enzyme or other non-LTR site specific retrotransposon element comprises a targeting domain, a reverse transcriptase domain, and a nickase domain. Also disclosed are cells edited using such a genome editing system, methods for editing a genome, and compositions comprising cells edited with this genomic editing system.
The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are structural information on the Cas protein of the CRISPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system. In particular the present invention comprehends optimized functional CRISPR-Cas enzyme systems.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/90 - Stable introduction of foreign DNA into chromosome
The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.
A multiscale composite materials with few or no void defects are described. The composite materials include a network of porous materials. Methods and systems for the fabrication of the composite materials are generally described. According to certain embodiments, composite materials are fabricated without the use of an autoclave or low pressure environments.
B32B 37/18 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the properties of the layers with all layers existing as coherent layers before laminating involving the assembly of discrete sheets or panels only
B32B 7/12 - Interconnection of layers using interposed adhesives or interposed materials with bonding properties
B32B 7/03 - Layered products characterised by the relation between layers; Layered products characterised by the relative orientation of features between layers, or by the relative values of a measurable parameter between layers, i.e. products comprising layers having different physical, chemical or physicochemical propert; Layered products characterised by the interconnection of layers with respect to the orientation of features
B32B 5/02 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by structural features of a layer comprising fibres or filaments
B32B 3/20 - Layered products essentially comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar form; Layered products essentially having particular features of form characterised by a discontinuous layer, i.e. apertured or formed of separate pieces of material characterised by an internal layer formed of separate pieces of material of pieces with channels or cavities
B32B 37/06 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the heating method
88.
MICROFLUIDIC TISSUE BIOPSY AND IMMUNE RESPONSE DRUG EVALUATION DEVICES AND SYSTEMS
This disclosure describes microfluidic tissue biopsy and immune response drug evaluation devices and systems. A microfluidic device can include an inlet channel having a first end configured to receive a fluid sample optionally containing a tissue sample. The microfluidic device can also include a tissue trapping region at the second end of the inlet channel downstream from the first end. The tissue trapping region can include one or more tissue traps configured to catch a tissue sample flowing through the inlet channel such that the fluid sample contacts the tissue trap. The microfluidic device can also include one or more channels providing an outlet.
Self-actuating articles including, for example, self-actuating needles and/or self-actuating biopsy punches, are generally provided. Advantageously, the self-actuating articles described herein may be useful as a general platform for delivery of a wide variety of pharmaceutical drugs that are typically delivered via injection directly into tissue due to degradation in the GI tract. The self-actuating articles described herein may also be used to deliver sensors and/or take biopsies without the need for an endoscopy. In some embodiments, the article comprises a spring (e.g., a coil spring, a beam, a material having particular mechanical recovery characteristics). Those of ordinary skill in the art would understand that the term spring is not intended to be limited to coil springs, but generally encompass any reversibly compressive material and/or component which, after releasing an applied compressive force on the material/component, the material/component substantially returns to an uncompressed length of the material/component (e.g., the within 95% of the length of the material/component prior to compression).
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61J 3/07 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
A61K 9/00 - Medicinal preparations characterised by special physical form
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
A61B 10/02 - Instruments for taking cell samples or for biopsy
A61M 37/00 - Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
A61N 1/32 - Applying electric currents by contact electrodes alternating or intermittent currents
A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/32 - Syringes - Details - Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
The present disclosure relates to synthetic oncolytic viruses comprising a lipid nanoparticle comprising one or more types of lipid and a self-amplifying replicon RNA comprising a sequence that encodes an immunomodulatory molecule.
Physical features of an object from tactile robotic exploration, including by manipulation of the object with an effector having a tactile sensor that provides measurements representative of physical interaction of the effector and the object. This exploration may include performing a predetermined set of manipulations of the object using the effector. Measurements made during the manipulations are used to form a data representation of physical characteristics of the object, and this data representation is used to control further motion of the object.
An exemplary imaging system is provided. The imaging system includes a light source configured to illuminate a plurality of spatially separated regions of a material structure producing a first illumination. A lens produces an image of the spatially separated regions. A lens array magnifies the spatially separated regions of the image. The lens array produces a mosaic image comprised of magnified subimages of each region spatially separated region. A camera sensor to record the image.
Topological qubits are provided in a quantum spin liquid. In various embodiments, a device is provided comprising a two-dimensional array of particles, each particle disposed at a vertex of a ruby lattice having a parameter ρ greater than
Topological qubits are provided in a quantum spin liquid. In various embodiments, a device is provided comprising a two-dimensional array of particles, each particle disposed at a vertex of a ruby lattice having a parameter ρ greater than
1
2
;
Topological qubits are provided in a quantum spin liquid. In various embodiments, a device is provided comprising a two-dimensional array of particles, each particle disposed at a vertex of a ruby lattice having a parameter ρ greater than
1
2
;
each particle having a first state and an excited state; each particle that belongs to at least three unit cells of the ruby lattice having a blockade radius, when in the excited state, sufficient to blockade each of at least six nearest neighboring particles in the ruby lattice from transitioning from its first state to its excited state, and wherein the array has at least one outer edge configured to be in a first boundary condition.
Described herein are systems, methods, and compositions capable of targeting nucleic acids. Describe in certain exemplary embodiments herein are a class of small Cas proteins (Type II-D Cas proteins) and systems thereof. Also described in certain exemplary embodiments herein are methods of modifying target sequences using the class of small Cas proteins (Type II-D Cas proteins) and systems thereof described herein.
A drug delivery device may be configured to delivery an active pharmaceutical ingredient (API) to a subject via the subject's oral-gastrointestinal (GI) tract. The drug delivery device may be configured to deliver a payload of an API while within the GI tract of the subject. The drug delivery device may include a reservoir, a potential energy source, a plurality of outlets, and a plurality of valves, wherein each outlet has a corresponding valve. The drug delivery device may further include a sensor configured to sense the direction of gravity, and the valves may be selectively opened based on a sensed direction of gravity. Thus, the drug delivery device may dispense a dose of API within the GI tracts of the subject based at least in part on the sensed direction of gravity.
Disclosed herein are methods and systems for correlating continuous physiological processes (e.g., electrophysiological activity) and biomolecular processes (e.g., gene expression) in cells within a tissue. Also disclosed herein are methods for preparing a tissue for continuous electrophysiological recording. Further disclosed herein are systems comprising nanoelectronic devices within cells in a tissue, wherein each nanoelectronic device comprises a unique electronic barcode. The methods and systems described herein comprise any tissue with electrical activity (e.g., brain tissue, heart tissue, nervous system tissue, muscle tissue, pancreas tissue, or gastrointestinal tract tissue). Additionally disclosed herein are methods for disease modeling, methods for discovering a target for treating a disease, and methods for drug screening.
Provided herein are feedback controller circuits and cell state classifiers for tunable phosphorylation-based transcriptional regulation of gene expression in cells based on intracellular miRNA profiles and degradation by small molecules. Also provided are methods of using feedback controller circuits and cell state classifiers for determining the cell state, and methods of treating cells and subjects using feedback controller circuits and cell state classifiers encoding therapeutic output molecules.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
The subject matter disclosed herein is generally directed to methods and compositions for stable transduction of target cells with libraries of genetic elements. The invention reduces intermolecular recombination between library elements and integration of multiple genetic elements.
patents
